CD8A and cancer: Indeed, treatments with PEGylated IL‐2, NKTR‐214 (developed by Nektar therapeutics) increased cytotoxic immune cell populations, including CD8+T and NK cells, with a limited effect on Treg cell expansion in both cancer patients and preclinical models.39, 40